Compare ARK Genomic Revolution ETF (ARKG) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Paychex, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.28, while Paychex, Inc. trades at $110.41 (market cap $38.25B). The key difference: Paychex, Inc. pays a 4.43% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Paychex, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | PAYX | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $147.99 |
52-Week Low | $23.09 | $85.57 |
Market Cap | — | $38.25B |
Enterprise Value | — | $41.73B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Paychex (PAYX) trades at $107.54, up 1.16% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 27.03% net margin and 44.77% ROE, though valuation ratios like P/E of 22 and P/S of 5.95 are elevated. Recent Q1 2026 EPS of $1.32 beat expectations, and the company maintains dividend payments with a $1.19 distribution scheduled for May 29, 2026. Cash flow from operations remains robust at $1.90B for 2025.
Outlook is cautiously optimistic with a consensus price target of $110.00, though analyst ratings are mixed (63.33% Hold). Key risks include macroeconomic sensitivity to small business hiring and integration challenges from acquisitions. The stock's current price near resistance at $110 suggests limited near-term upside without significant catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
